NPNikolina Penava

Nikolina Penava

*This is an algorithmically generated author record based on publicly available information.

Nikolina Penava has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Ćuk

    Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina; Faculty of Pharmacy, University of Mostar, Mostar, Bosnia and Herzegovina image/svg+xml

    2 shared publications
  • Dejan Tiric

    Department of Obstetrics and Gynecology, University Clinical Hospital Mostar, 88000 Mostar, Bosnia and Herzegovina

    2 shared publications
  • Vajdana Tomić

    Faculty of Health Studies, University of Mostar, 88000 Mostar, Bosnia and Herzegovina

    2 shared publications
  • Andrea Prce

    Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina image/svg+xml

    1 shared publication
  • Ante Pusic

    Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina image/svg+xml

    1 shared publication
  • Ivanka Mikulic

    Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina; Faculty of Pharmacy, University of Mostar, Mostar, Bosnia and Herzegovina image/svg+xml

    1 shared publication

Latest Publications

  • Open Access

    Ferroportin and soluble transferrin receptor in women with first-trimester missed abortion

    by Ana Cuk, Lada Rumora, Ivanka Mikulic, Nikolina Penava, Ivona Cvetkovic, Vinka Mikulic, Kristina Ljubic, Ante Pusic, Andrea Prce, Dejan Tiric, et al.

    Laboratory diagnostics of iron homeostasis during pregnancy typically rely on routine parameters, which often inadequately reflect the actual maternal iron status. This study aimed to evaluate the investigative and diagnostic utility of soluble transferrin receptor (sTfR) and ferroportin (Fpn) concentrations as key indicators of iron dysregulation in women with normal early pregnancy and those experiencing missed abortion. These primary biomarkers were assessed in conjunction with standard laboratory parameters of iron status across the study groups. Notably, Fpn concentration had not previously been determined in women with either normal or abnormal pregnancies. The study enrolled 45 women with missed abortion and 45 women with normal first-trimester pregnancies. Peripheral blood concentrations of iron (Fe), unsaturated iron-binding capacity (UIBC), ferritin, hemoglobin (Hb), transferrin, and sTfR were measured using automated analyzers, while hepcidin and Fpn were quantified using ELISA kits. Transferrin saturation (TSAT), the sTfR/log ferritin index (sTfR-F index), and the ferroportin to soluble transferrin receptor ratio (Fpn/sTfR) were calculated. In the missed abortion group, Fpn (p < 0.001), Fe (p = 0.008), TSAT (p = 0.018), and Fpn/sTfR (p < 0.001) were significantly decreased, whereas sTfR (p = 0.001) and the sTfR-F index (p = 0.003) were significantly increased compared to women with normal pregnancies. Proposed multiparameter models incorporating sTfR and Fpn, or sTfR, hepcidin, and Fpn, accurately classified over 80% of cases and demonstrated excellent area under the curve (AUC) values of approximately 0.9. These findings indicate that Fpn and sTfR may serve as valuable investigative biomarkers for identifying dysregulation of iron homeostasis in early pregnancy.

  • Open Access

    Low-dose prednisone and pregnancy prolongation in threatened preterm birth a randomized pilot study

    by Nikolina Penava, Ana Ćuk, Dejan Tirić, Oliver Vasilj, Vajdana Tomić, Vedran Stefanovic

    Objectives: To compare pregnancy prolongation and neonatal outcomes in women with signs of threatened preterm birth (PTB) and intact membranes by administration of low-doses of prednisone for 3 weeks compared to women who received standard protocols of tocolysis and respiratory distress syndrome (RDS) prophylaxis in a pilot randomized controlled trial. Methods: We randomized 26 women with signs of threatened PTB and intact membranes between 24 and 34 weeks of gestation to either continued prednisone administration for 3 weeks following the initiation of the standard protocol (intervention group) or standard therapy for threatened PTB (control group). The primary outcome was the gestational length in women with and without using low-doses of prednisone. The secondary outcome included incidence of RDS, intraventricular hemorrhage, necrotizing enterocolitis, the need for mechanical ventilation, and perinatal mortality in newborns from both study groups. Results: Participants in the intervention group had significantly longer pregnancy prolongation than the control group (65.38 vs. 40.54 days, p=0.001). Although the difference was not statistically significant (p=0.153), the gestational age at delivery in the intervention group (38.35 weeks) was 10 days longer than in the control group (36.89 weeks). There were no significant differences between the groups in neonatal outcomes. Conclusions: The first pilot randomized controlled study on low-dose prednisone in threatened PTB and intact membranes suggests it may prolong pregnancy without adverse neonatal outcomes. Due to the small sample size and single-centre design, these preliminary findings should be interpreted with caution and confirmed in larger, adequately powered trials.